Table 1.
Clinical characteristics of patients with ovarian cancer
| Variable | Median (range) |
|---|---|
| Age | 50 (18-89) |
| BMI (kg/m2) | 22.9 (16.5-29.8) |
| Histologic subtype, n (%) | |
| Serous | 156 (69.3) |
| Endometrioid | 25 (11.1) |
| Transitional cell | 20 (9.0) |
| Clear cell | 12 (5.3) |
| Mucinous | 11 (4.9) |
| Other | 1 (0.4) |
| FIGO Stage, n (%) | |
| I | 62 (27.6) |
| II | 39 (17.3) |
| III | 109 (48.4) |
| IV | 15 (6.7) |
| Histological grade, n (%) | |
| G1 | 42 (18.7) |
| G2 | 48 (21.3) |
| G3 | 135 (60.0) |
| Malignant ascites, n (%) | |
| Yes | 134 (59.6) |
| No | 91 (40.4) |
| Lymph node metastases, n (%) | |
| Yes | 86 (38.2) |
| No | 139 (61.8) |
| White blood cell*109 | 7.25 (3.3-16.5) |
| Lymphocyte*109 | 1.27 (0.3-2.8) |
| Monocyte*109 | 0.39 (0.1-1.6) |
| LMR | 3.5 (0.5-18.0) |
| Serum CA125 (U/mL) | 161 (1.8-5672.6) |
BMI, body mass index; FIGO, Federation of Gynecologists and Obstetricians; LMR, lymphocyte/monocyte ratio; CA125, cancer antigen 125.